Home 2017
Archives
ASCO: Agreement Lacking With ESMO on Most Effective Drugs
Negative correlation identified for ASCO benefit score with monthly incremental drug costs
ASCO: Recent Drop in Additional Surgery Post Lumpectomy
Decrease was concomitant with 2014 consensus statement endorsing a margin of no ink on tumor
ASCO: Novel Meds Show Promise in Advanced NSCLC
Results presented from two phase III trials
ASCO: CAR T-Cell Therapy Promising in Multiple Myeloma
Findings from trial of chimeric antigen receptor T cells targeting B-cell maturation protein
ASCO: SWOG Trials Have Had Considerable Impact on Cancer
Estimated 3.34 million life-years gained through 2015 from 23 positive SWOG treatment trials
ASCO: Industry Perks Influence Physicians’ Choice of Cancer Rx
Even relatively small payments appear to make a difference, researchers say
ASCO: Olaparib Efficacious in BRCA-Related Breast Cancer
May offer a new treatment for women with advanced BRCA-related disease, researchers say
ASCO: Survival Up With Patient-Reported Outcomes During CA Tx
Improved survival with patient-reported outcomes for symptom monitoring in metastatic cancer
ASCO: Gene-Targeted Drug Shows Efficacy for Child, Adult Cancers
Larotrectinib targets tropomyosin receptor kinase fusion proteins
ASCO: Abiraterone Extends Survival in Metastatic Prostate CA
Side effects noted with use of abiraterone similar to those already found in patients taking the drug
